The recent endorsement of psychedelic therapies by Health Secretary Robert F. Kennedy Jr. and a cohort of former Trump administration officials marks an unusual development in American health policy. MDMA, commonly known as ecstasy or Molly, has been illegal under U.S. federal law since 1985. It is classified as a Schedule I substance, alongside drugs like marijuana and psilocybin. In the aftermath of the FDA’s recent rejection of MDMA-assisted therapy for veterans’ PTSD during the Biden administration, a new, growing coalition of political figures is pressing for a reassessment of how psychedelic compounds might be used to treat mental illnesses.

Advocacy Realignment

By July 2025, support for psychedelics had moved beyond its traditional base. Kennedy, along with former Trump officials Ben Carson and Jerome Adams, expressed interest in advancing psychedelic therapies for hard-to-treat mental health conditions, “This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months.” said Kennedy to Congress, as reported by AP News.

Historically, MDMA has long been tied to counterculture movements, criminalized in the 1980s, and associated with raves and progressive reform circles. The involvement of more mainstream and conservative figures is a shift in the voices advocating for these therapies, moving the issue into bipartisan territory.

Regulatory Caution and Potential Reconsideration

Within the past year, federal regulators have pushed back. In June 2024, the FDA’s advisory committee voted 10 to 1 against approving MDMA therapy for PTSD due to concerns about “flawed data and questionable research”. More specifically, panelists raised concerns about unblinded study designs that may have biased results, the potential for therapist influence on participants’ responses, and insufficient long-term safety data, resulting in the ultimate conclusion that the results, while promising, were not reliable enough to justify approval at this stage.

However, the agency has demonstrated openness to reconsideration. FDA Chief Marty Makary explained to Kennedy that the review of MDMA and similar psychedelic treatments is a “top priority” and outlined new initiatives to accelerate approval. 

Veteran Branding

Veterans have become a central focus in the effort to advance psychedelic medicine. Organizations like the Veterans Mental Health Leadership Coalition have pushed lawmakers to prioritize research into MDMA-assisted therapy, framing it as a moral obligation to support those who served. Through centering veterans, figures who often facilitate bipartisan respect, advocates are depoliticizing the issue and expanding its reach. 

But this also raises an equity concern: If veteran-focused appeals drive legislative action, will similar support be extended to other marginalized groups experiencing trauma, such as incarcerated populations or those with treatment-resistant depression, who lack similar symbolic capital?

State-Level Legislation

Oregon became the first state to legalize the supervised use of psilocybin in 2023 due to recent research supporting the treatment of PTSD, depression, end-of-life anxiety, and other mental health concerns. Colorado followed in 2022, decriminalizing certain natural psychedelics and creating a regulated access model for psilocybin therapy. Other states, including California and Washington, are considering similar legislation. 

Next Steps and Conclusion

Looking ahead, research into psychedelic therapies is expanding rapidly as interest and publicity grow. A 2022 Johns Hopkins study funded by the NIH found that psilocybin-assisted treatment significantly eased major depression symptoms, with benefits lasting up to a year for some patients.

The political landscape around psychedelic therapy is dynamic, bringing together voices from across the spectrum. Although this growing support offers an opportunity to rethink mental health treatment, it also introduces a new challenge: policymakers must balance the public demand with standards of scientific evaluation.